HK Stock Market Move | PEIJIA-B (09996) is currently up over 3%, with the chairman increasing his shareholding in the company on the open market. Several products are about to make significant progress.

PEIJIA-B (09996) is now up over 3%, as of the time of writing, it is up 2.6% at HKD 5.92, with a turnover of HKD 8.9349 million. On the news front, on December 5th, Peijia Medical announced that Dr. Zhang Yibo, Executive Director, Chief Executive Officer, and Chairman of the Board of Directors, will start buying company shares on the open market starting from December 1st, 2025. The total cost of increasing his shareholding is expected to be no more than HKD 15 million. According to the announcement, Dr. Zhang will not rule out the possibility of further increasing his shareholding in the company at the appropriate time in accordance with applicable laws and regulations. China Securities Co., Ltd. released a research report stating that the company's TAVR products continue to increase in volume, and market share is steadily increasing. The GeminiOne TEER system, TaurusTrio aortic regurgitation valve, and TaurusNXT bioprosthetic TAVR are expected to be approved intensively from the end of 2025 to 2026, driving accelerated growth in the valve business. The MonarQ tricuspid valve system has initiated global clinical trials, and the cutting-edge technology business has received external financing, with a clear path for innovation to go global.